ONO 1301
ONO 1301 structure
|
Common Name | ONO 1301 | ||
|---|---|---|---|---|
| CAS Number | 176391-41-6 | Molecular Weight | 428.48000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H24N2O4 | Melting Point | 147-158 °C | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Inhibition of cyclooxygenase-2 causes a decrease in coronary flow in diabetic mice. The possible role of PGE2 and dysfunctional vasodilation mediated by prostacyclin receptor.
J. Physiol. Biochem. 71 , 351-8, (2015) Several lines of evidence suggest that cyclooxygenase-2 (COX-2) activity can have a beneficial role in the maintenance of vascular tone of the blood vessels in diabetes. Specifically, the increased production of prostacyclin (PGI2) and prostaglandin E2 (PGE2)... |
|
|
Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage.
Clin. Exp. Med. 15 , 245-53, (2015) Chemokines play essential roles during inflammatory responses and in pathogenesis of inflammatory diseases. Monocyte chemotactic protein-1 (MCP-1) is a critical chemokine in the development of atherosclerosis and acute cardiovascular syndromes. MCP-1, by its ... |
|
|
ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells.
Acta Med. Okayama 69(1) , 1-15, (2015) Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage renal disease. Considering the increasing prevalence of type 2 diabetes mellitus worldwide, novel therapeutic approaches are urgently needed. ONO-1301 is a novel ... |
|
|
A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice.
Clin. Exp. Allergy 40(2) , 317-26, (2010) ONO-1301 is a novel drug that acts as a prostacyclin agonist with thromboxane A(2) (TxA(2)) synthase inhibitory activity. We investigated the effect of ONO-1301 on development of airway allergic inflammation.Mice sensitized and challenged to ovalbumin (OVA) r... |
|
|
Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model.
Am. J. Physiol. Renal Physiol. 302(12) , F1616-29, (2012) Tubulointerstitial injuries are crucial histological alterations that predict the deterioration of renal function in chronic kidney disease. ONO-1301, a novel sustained-release prostacyclin analog, accompanied by thromboxane synthase activity, exerts therapeu... |
|
|
Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression.
Am. J. Physiol. Gastrointest. Liver Physiol. 302(4) , G420-9, (2012) Previous studies have demonstrated that mice disrupted with the cyclooxygenase-2 gene showed much more severe liver damage compared with wild-type mice after liver injury, and prostaglandins (PGs) such as PGE(1/2) and PGI(2) have decreased hepatic injury, but... |
|
|
Effect of antioxidants on the stability of ONO-1301, a novel long-acting prostacyclin agonist, loaded in PLGA microspheres.
J. Microencapsul. 30(3) , 245-56, (2013) The purpose of this study was to investigate the physicochemical stability of ONO-1301 in poly(lactide-co-glycolide) microspheres (PLGA MS) under storage for 28 days in the absence or presence of butylated hydroxytoluene (BHT) or α-tocopherol as antioxidant. ... |
|
|
Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion.
J. Pharm. Pharmacol. 64(3) , 353-9, (2012) ONO-1301 was developed as a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. In this study, we investigated the therapeutic time window of oral ONO-1301 and the effect of a single subcutaneous injection of ONO-1301-loaded ... |
|
|
The effect of treatment with a sustained-release prostacyclin analogue (ONO-1301-loaded PLGA microsphere) on short-term memory impairment in rats with transient global cerebral ischemia.
J. Microencapsul. 29(3) , 211-8, (2012) The purpose of this study was to prepare the ONO-1301 loaded poly(lactide-co-glycolide) microsphere (ONO-1301 PLGA MS) and to evaluate neuroprotective effects for short-term memory by a single subcutaneous injection of ONO-1301 PLGA MS on repeated induction o... |
|
|
Differential effect of prostaglandins E1 and E2 on lipopolysaccharide-induced adhesion molecule expression on human monocytes.
Eur. J. Pharmacol. 512(2-3) , 223-30, (2005) The effect of prostaglandins E1 and E2 on the 1 ng/ml lipopolysaccharide-induced expression of intercellular adhesion molecule (ICAM)-1, B7.1, B7.2, CD40 and CD40 ligand (CD40L) on monocytes was examined. Prostaglandin E1 suppressed B7.1 and CD40 expression, ... |